Ropeginterferon alfa-2b, a novel IFNα-2b, induces high ...

Ropeginterferon alfa-2b, a next-generation mono-pegylated IFN-α-2b, showed promising efficacy and safety in a phase 1/2 study with 51 polycythemia vera patients. Administered every 2 weeks, it achieved a 90% overall response rate without dose-limiting toxicities. The study supports its development in a phase 3 trial.